Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer

Ganesh V. Raj, Harry Herr, Angel M. Serio, Sherri M. Donat, Bernard H. Bochner, Andrew J. Vickers, Guido Dalbagni

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Purpose: Historically patients with recurrent T1 bladder tumors after bacillus Calmette-Guerin have been treated with bladder sparing approaches. Recently a paradigm shift has occurred since patients are increasingly offered radical cystectomy before disease progression to muscle invasion. In this study we explored the effect of this paradigm shift on progression rates and disease specific survival. Materials and Methods: The historical cohort consisted of 307 patients from 3 prospective intravesical bacillus Calmette-Guerin protocols from 1980 to 1989. An institutional review board approved review identified 589 patients treated with bacillus Calmette-Guerin in a contemporary cohort from 1992 to 2004. Results: In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin. Of these 85 patients 60 had progression to muscle invasive disease. At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%). In the contemporary cohort 129 patients had documented T1 recurrence. In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%). Conclusions: Preemptive radical cystectomy performed for recurrent T1 disease following intravesical bacillus Calmette-Guerin therapy may be associated with better disease specific survival.

Original languageEnglish (US)
Pages (from-to)1283-1286
Number of pages4
JournalJournal of Urology
Volume177
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Urinary Bladder Neoplasms
Mycobacterium bovis
Survival
Cystectomy
Recurrence
Incidence
Therapeutics
Muscles
Disease Progression
Research Ethics Committees
Urinary Bladder

Keywords

  • cystectomy
  • disease progression
  • mycobacterium bovis
  • treatment outcome

ASJC Scopus subject areas

  • Urology

Cite this

Raj, G. V., Herr, H., Serio, A. M., Donat, S. M., Bochner, B. H., Vickers, A. J., & Dalbagni, G. (2007). Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. Journal of Urology, 177(4), 1283-1286. https://doi.org/10.1016/j.juro.2006.11.090

Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. / Raj, Ganesh V.; Herr, Harry; Serio, Angel M.; Donat, Sherri M.; Bochner, Bernard H.; Vickers, Andrew J.; Dalbagni, Guido.

In: Journal of Urology, Vol. 177, No. 4, 04.2007, p. 1283-1286.

Research output: Contribution to journalArticle

Raj, GV, Herr, H, Serio, AM, Donat, SM, Bochner, BH, Vickers, AJ & Dalbagni, G 2007, 'Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer', Journal of Urology, vol. 177, no. 4, pp. 1283-1286. https://doi.org/10.1016/j.juro.2006.11.090
Raj, Ganesh V. ; Herr, Harry ; Serio, Angel M. ; Donat, Sherri M. ; Bochner, Bernard H. ; Vickers, Andrew J. ; Dalbagni, Guido. / Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. In: Journal of Urology. 2007 ; Vol. 177, No. 4. pp. 1283-1286.
@article{304a21496b1a47b4ad5d7b11d32965b8,
title = "Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer",
abstract = "Purpose: Historically patients with recurrent T1 bladder tumors after bacillus Calmette-Guerin have been treated with bladder sparing approaches. Recently a paradigm shift has occurred since patients are increasingly offered radical cystectomy before disease progression to muscle invasion. In this study we explored the effect of this paradigm shift on progression rates and disease specific survival. Materials and Methods: The historical cohort consisted of 307 patients from 3 prospective intravesical bacillus Calmette-Guerin protocols from 1980 to 1989. An institutional review board approved review identified 589 patients treated with bacillus Calmette-Guerin in a contemporary cohort from 1992 to 2004. Results: In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin. Of these 85 patients 60 had progression to muscle invasive disease. At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71{\%} (95{\%} CI 61{\%}, 81{\%}) and the cumulative incidence of death from disease was 48{\%} (95{\%} CI 39{\%}, 60{\%}). In the contemporary cohort 129 patients had documented T1 recurrence. In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28{\%} (95{\%} CI 20{\%}, 38{\%}) and the cumulative incidence of death from disease was 31{\%} (95{\%} CI 22{\%}, 42{\%}). Conclusions: Preemptive radical cystectomy performed for recurrent T1 disease following intravesical bacillus Calmette-Guerin therapy may be associated with better disease specific survival.",
keywords = "cystectomy, disease progression, mycobacterium bovis, treatment outcome",
author = "Raj, {Ganesh V.} and Harry Herr and Serio, {Angel M.} and Donat, {Sherri M.} and Bochner, {Bernard H.} and Vickers, {Andrew J.} and Guido Dalbagni",
year = "2007",
month = "4",
doi = "10.1016/j.juro.2006.11.090",
language = "English (US)",
volume = "177",
pages = "1283--1286",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer

AU - Raj, Ganesh V.

AU - Herr, Harry

AU - Serio, Angel M.

AU - Donat, Sherri M.

AU - Bochner, Bernard H.

AU - Vickers, Andrew J.

AU - Dalbagni, Guido

PY - 2007/4

Y1 - 2007/4

N2 - Purpose: Historically patients with recurrent T1 bladder tumors after bacillus Calmette-Guerin have been treated with bladder sparing approaches. Recently a paradigm shift has occurred since patients are increasingly offered radical cystectomy before disease progression to muscle invasion. In this study we explored the effect of this paradigm shift on progression rates and disease specific survival. Materials and Methods: The historical cohort consisted of 307 patients from 3 prospective intravesical bacillus Calmette-Guerin protocols from 1980 to 1989. An institutional review board approved review identified 589 patients treated with bacillus Calmette-Guerin in a contemporary cohort from 1992 to 2004. Results: In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin. Of these 85 patients 60 had progression to muscle invasive disease. At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%). In the contemporary cohort 129 patients had documented T1 recurrence. In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%). Conclusions: Preemptive radical cystectomy performed for recurrent T1 disease following intravesical bacillus Calmette-Guerin therapy may be associated with better disease specific survival.

AB - Purpose: Historically patients with recurrent T1 bladder tumors after bacillus Calmette-Guerin have been treated with bladder sparing approaches. Recently a paradigm shift has occurred since patients are increasingly offered radical cystectomy before disease progression to muscle invasion. In this study we explored the effect of this paradigm shift on progression rates and disease specific survival. Materials and Methods: The historical cohort consisted of 307 patients from 3 prospective intravesical bacillus Calmette-Guerin protocols from 1980 to 1989. An institutional review board approved review identified 589 patients treated with bacillus Calmette-Guerin in a contemporary cohort from 1992 to 2004. Results: In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin. Of these 85 patients 60 had progression to muscle invasive disease. At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%). In the contemporary cohort 129 patients had documented T1 recurrence. In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%). Conclusions: Preemptive radical cystectomy performed for recurrent T1 disease following intravesical bacillus Calmette-Guerin therapy may be associated with better disease specific survival.

KW - cystectomy

KW - disease progression

KW - mycobacterium bovis

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=33947258389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947258389&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.11.090

DO - 10.1016/j.juro.2006.11.090

M3 - Article

C2 - 17382713

AN - SCOPUS:33947258389

VL - 177

SP - 1283

EP - 1286

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -